WAMLOX 10MG/160MG Potahovaná tableta สาธารณรัฐเช็ก - เช็ก - SUKL (Státní ústav pro kontrolu léčiv)

wamlox 10mg/160mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan - potahovaná tableta - 10mg/160mg - valsartan a amlodipin

WAMLOX 5MG/160MG Potahovaná tableta สาธารณรัฐเช็ก - เช็ก - SUKL (Státní ústav pro kontrolu léčiv)

wamlox 5mg/160mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan - potahovaná tableta - 5mg/160mg - valsartan a amlodipin

WAMLOX 5MG/80MG Potahovaná tableta สาธารณรัฐเช็ก - เช็ก - SUKL (Státní ústav pro kontrolu léčiv)

wamlox 5mg/80mg potahovaná tableta

krka, d.d., novo mesto, novo mesto array - 12990 amlodipin-besilÁt; 13182 valsartan - potahovaná tableta - 5mg/80mg - valsartan a amlodipin

TONARSSA 2,85MG/2,5MG Tableta สาธารณรัฐเช็ก - เช็ก - SUKL (Státní ústav pro kontrolu léčiv)

tonarssa 2,85mg/2,5mg tableta

krka, d.d., novo mesto, novo mesto array - 13049 perindopril-erbumin; 12990 amlodipin-besilÁt - tableta - 2,85mg/2,5mg - perindopril a amlodipin

TONARSSA 5,7MG/5MG Tableta สาธารณรัฐเช็ก - เช็ก - SUKL (Státní ústav pro kontrolu léčiv)

tonarssa 5,7mg/5mg tableta

krka, d.d., novo mesto, novo mesto array - 13049 perindopril-erbumin; 12990 amlodipin-besilÁt - tableta - 5,7mg/5mg - perindopril a amlodipin

Edarbi สหภาพยุโรป - เช็ก - EMA (European Medicines Agency)

edarbi

takeda pharma a/s - azilsartan medoxomil - hypertenze - agens působící na systém renin-angiotenzin - přípravek edarbi je určen k léčbě esenciální hypertenze u dospělých.

Eucreas สหภาพยุโรป - เช็ก - EMA (European Medicines Agency)

eucreas

novartis europharm limited - vildagliptin, metformin hydrochloridu - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.